

Structure and Property Based Design of Pyrazolo[1,5-a]pyrimidine Inhibitors of CK2 Kinase with Activity in Vivo


James E. Dowling,* Marat Alimzhanov, Larry Bao, Michael H. Block, Claudio Chuaqui, Emma L. Cooke, Christopher R. Denz, Alex Hird, Shan Huang, Nicholas A. Larsen, Bo Peng, Timothy W. Pontz, Caroline Rivard-Costa, Jamal Carlos Saeh, Kumar Thakur, Qing Ye, Tao Zhang, and Paul D. Lyne

AstraZeneca, Oncology Innovative Medicines Unit, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States

Supporting Information

ABSTRACT: In this letter, we describe the design, synthesis, and structure–activity relationship of 5-anilinopyrazolo[1,5-a]pyrimidine inhibitors of CK2 kinase. Property-based optimization of early leads using the 7-oxetan-3-yl amino group led to a series of matched molecular pairs with lower lipophilicity, decreased affinity for human plasma proteins, and reduced binding to the hERG ion channel. Agents in this study were shown to modulate pAKT^{S129}, a direct substrate of CK2, in vitro and in vivo, and exhibited tumor growth inhibition when administered orally in a murine DLD-1 xenograft.

KEYWORDS: CK2 kinase, pyrazolo[1,5-a]pyrimidine, matched molecular pair, oxetane



The serine/threonine protein kinase CK2, a tetrameric complex containing two catalytic (α or α') and two regulatory (β) subunits, controls cell growth, proliferation, and evasion of apoptosis by phosphorylation of a range of substrates in critical cellular signaling pathways including PI3K (phosphatidylinositol 3-kinase)/AKT (protein kinase B), NF κ B (nuclear factor kappa-light-chain-enhancer of activated B cells) and Wnt (wingless type MMTV integration site family).^{1–3} Overexpression of the CK2 α subunit correlates with tumor aggressiveness and disease severity in certain cancers, while compensatory increases in CK2 α' levels have been observed in response to RNAi treatment in mice.^{4,5} Several academic and industrial research groups have been actively engaged in developing small molecule inhibitors of CK2 to provide further pharmacological validation of the compelling in vitro and in vivo data amassed to date.⁶ The recent discovery of CX-4945, a selective, orally available inhibitor of CK2 by researchers from Cylene, represents an important first step in evaluating the clinical potential of this novel target in man.⁷ We have recently described the design of a series of conformationally constrained inhibitors of CK2 containing the pyrazolo[1,5-a]pyrimidine nucleus.⁸ Members of this series of compounds exhibited potent inhibition of the enzyme, possessed a high degree of kinase selectivity, and depleted cellular levels of pAKT^{S129}, a direct substrate of CK2 believed to hyperactivate the AKT pathway.⁹ Although our attempts to enhance both cellular potency and physical properties in this series were unsuccessful, these studies resulted in an understanding of the structure–property relationships within the scaffold and provided additional insights into ligand–receptor binding. In particular, we found that *N*-methylation of the acetamide of **1a**, to give ring-constrained analogue **1b**, preserved enzymatic and

cellular activity. In subsequent designs, we proposed to release the constraint in **1b** and introduce a new conformational constraint, exemplified by indoline **2**, that would enforce the crystallographically observed cisoid conformation of the acetamide in **1** (Figure 1). Compound **2** is a potent inhibitor




Figure 1. Design of conformationally constrained acetamide **2** and ortho-substituted anilines (**3**).

Received: May 23, 2013


Accepted: July 3, 2013

Published: July 3, 2013

of CK2 in biochemical and cellular assays; however, it exhibits low aqueous solubility at physiological pH (sol. = 4 μM) and high intrinsic clearance when incubated with rat liver microsomes ($\text{CL}_{\text{int}} = 120 \mu\text{L}/\text{min}/\text{mg}$). We postulated that either the *N*-acetyl group or the methylene groups within the newly introduced five-membered ring represented potential sites of metabolism and chose instead to focus on other variations of the pharmacophore. The potency of **2** established that the position ortho to the acetamide could be functionalized, and we subsequently prepared a series of *N*-(3-aminoaryl)acetamide analogues (**3**) to evaluate the scope of substituents that might be accommodated on the aryl ring (Figure 1). Herein, we describe our efforts to build on the enzymatic potency and kinase selectivity profile of **1a**, while striving for an acceptable balance of physical properties and ADME characteristics that would enable us to carry out pharmacodynamic and disease model studies using an orally administered agent.

The synthesis of **2** and related analogues was carried out by adapting the convergent approach described in our earlier work (Scheme 1).⁸ Installation of functionality at C7 was

Scheme 1a



^aReagents and conditions: (a) amine, EtOH, 25 °C; (b) Pd(OAc)₂, Xantphos, Cs₂CO₃, DMA (*N,N*-dimethyl acetamide)/H₂O (4:1), 150 °C, μwave , 0.5 h; (c) Pd₂(dba)₃, Xantphos, Cs₂CO₃, DMA (*N,N*-dimethyl acetamide)/H₂O (4:1), 150 °C, μwave , 0.5 h; (d) Pd₂(dba)₃, di-*tert*-butyl(2',4',6'-triisopropylbiphenyl-2-yl)phosphine, Cs₂CO₃, DMA/H₂O (4:1), 140 °C, μwave , 0.5 h; (e) KF, NMP, 150 °C 5 h.

accomplished by displacement of the 7-chloro group in 5,7-dichloro-3-cyano-pyrazolo[1,5-*a*]pyrimidine (**4**) to afford intermediates of general structure **5**. Substitution at C5 was subsequently achieved by palladium catalyzed¹⁰ or KF-promoted coupling of **5** with the requisite *N*-(3-aminoaryl)-acetamide (**6**) to furnish the desired analogues (**7a–l**).

Introduction of *N*-(3-aminophenyl)acetamides bearing chloro (**7a**) and small alkyl groups (**7b–d**) at the 6-position increased the half-maximum inhibitory potency below the limit of detection ($\text{IC}_{50} < 3 \text{ nM}$) in our enzymatic assay, which measures the inhibition of recombinant human full length CK2 α mediated phosphorylation of a synthetic peptide substrate at K_m ATP concentration (Table 1).¹¹ Among the

C6 alkyl substituted derivatives, the methyl (**7b**) isopropyl (**7c**) and cyclopropyl (**7d**) analogues exhibit comparable activity in a mechanistic cellular assay that measures levels of the CK2 substrate pAKT^{S129} in an ELISA format. Introduction of a nitrogen atom in the aniline ring, to afford pyridyl analogues **7g** and **7h**, reduced cellular potency relative to **7b**, with a negligible effect on solubility. We subsequently evaluated the effect of varying the substituent at the hinge-binding N7 position and found that five-membered heterocyclic substituents (**7k,l**) preserved enzymatic activity but, with the exception of *N*-methyl imidazole (**7l**), adversely affected solubility. With the enzymatic and mechanistic cellular activity of compounds in this series routinely reading out at or below the lower limits of detection in the respective assays, we began to guide our structure–activity relationship (SAR) studies with the aid of phenotypic assays using colorectal (HCT-116, DLD-1) and other cultured cell lines.

An X-ray cocrystal structure determination of **7l** with recombinant human CK2 at 2.2 Å resolution revealed the inhibitor to bind as expected with N2 of the pyrazolo[1,5-*a*]pyrimidine core and the C7 NH interacting with the hinge region of the ATP-binding pocket (Figure 2).¹² As noted previously, critical to the high binding affinity of this inhibitor class is the engagement with a buried water molecule adjacent to the gatekeeper residue (Phe¹¹³). The energetically disfavored cisoid conformation adopted by the acetamide enables the carbonyl group to coordinate with the water molecule and with Lys⁶⁸ and permits formation of a hydrogen bond between the acetamide NH and Asp¹⁷⁵. The sum of these interactions, in addition to further coordination of the water molecule by the cyano group (3.0 Å) appears sufficient to compensate for the higher energy form of the acetamide. Deletion of the 3-cyano group from **7b** to give des-cyano analogue **8** (not shown) results in a >100-fold reduction in enzymatic potency (CK2 $\text{IC}_{50} = 0.27 \mu\text{M}$) and loss of measurable cellular activity (pAKT^{S129} $\text{IC}_{50} > 3.3 \mu\text{M}$). A similar potency decrease was observed with the des-cyano analogue of indole **1a**.⁸ In addition, we believe the increased potency of the anilino-compounds relative to **1a** is due to steric reinforcement of the cisoid amide geometry by the ortho-substituent. Preorganization of the amide in a conformation required for recognition by the kinase presumably decreases the entropy loss upon binding of the ligand and results in higher affinity. This substitution may be essential for increased cellular activity as well; the growth inhibitory effects (HCT-116 GI_{50}s) reported by Polaris for a series of related analogues lacking substitution ortho to the acetamide are 2–3 log units weaker than those in this study.¹³

The *N*-methyl group of the imidazole in **7l** is positioned at the interface with the solvent-accessible surface and suggests that further substitution at this position could be undertaken.

Through the intermediacy of hydroxyethyl derivatives **9a** and **9b**, we prepared a series of amine-containing analogues (Scheme 2). While our earlier attempts to modify indole **1a** by introducing hydrophilic groups on the C7 substituent resulted in decreased cellular potency, we were initially encouraged to find that *N*-substituted analogues of **7l** possessed high enzymatic and cellular activity (Table 2). In the pyrazole series (**10a** and **11a–c**), these modifications resulted in a modest five- to 10-fold decrease in cellular potency (pAKT^{S129}) yet maintained activity in the phenotypic assay in the sub-100 nM range. Despite possessing high aqueous solubility and low intrinsic clearance, the plasma concentrations of **11b–d** following a single oral dose in the rat were extremely low

Table 1. CK2 Biochemical and Cellular Potency for Compounds 7a–l

compd	CK2 α IC ₅₀ (nM) ^a	pAKT ^{S129} IC ₅₀ (nM) ^a	HCT-116 GI ₅₀ (nM) ^a	sol. (μ M) ^a	LogD ^a	Hu PPB (% free) ^a	microsomal stability ^b	hERG IC ₅₀ (μ M)
7a	<3	ND	300	<1	3.1	3	22	>33
7b	<3	2	81	8	2.4	8	15	21
7c	<3	ND	67	<1	3.0	4	56	>33
7d	<3	3	21	<1	3.1	2	39	19
7e	<3	2	57	5	2.3	13	36	16
7f	<3	2	12	7	2.8	9.6	19	ND
7g	<3	42	ND	18	2.1	15	50	>33
7h	<3	6	300	7	2.1	12	<4	19
7i	<3	33	600	<1	2.9	2.4	47	11
7j	<3	8	410	5	3.0	4.3	31	16
7k	<3	3	ND	1	2.1	12	<4	ND
7l	<3	10	110	52	0.8	21	20	ND

^aMean value of two experiments. Deviations were within $\pm 25\%$. ^bIntrinsic clearance (CL_{int}) determined from rat liver microsome incubations (μ L/min/mg); ND = not determined.





Figure 2. Human CK2 kinase in complex with 7l (PDB code: 4GUB) as determined at 2.2 Å resolution. The structure is oriented with the N-terminal lobe toward the top left, the C-terminal lobe toward the bottom right, and residues of the hinge region on the bottom left. The electron density ($2F_o - F_c$), contoured at 1σ , is shown as a wire mesh. Polar interactions ≤ 3.0 Å are indicated as dotted lines and bound water molecules are shown as red spheres.¹⁴

($C_{\max} < 0.1 \mu\text{M}$). This may be rationalized in part by considering the low measured permeability of 11b ($P_{\text{app}} A-B = 0.2 \times 10^{-6}$ cm/s) and high efflux (efflux ratio = 100) in MDR1 expressing LLCK cells. Similarly functionalized imidazoles (10b and 11d-f) exhibited a more significant drop off in cellular potency and were not profiled in vivo.

We next focused on a strategy for achieving further reduction in the lipophilicity of 7b and related compounds that would not rely on introduction of basic groups. In recent years, oxetanes

Scheme 2a



^aReagents and conditions: (a) 2-(4-amino-1H-pyrazol-1-yl)ethanol, $i\text{Pr}_2\text{NEt}$, EtOH, 25 °C; (b) 2-(4-amino-1H-imidazol-1-yl)ethanol, Et₃N, EtOH, 50 °C; (c) NMP, 140 °C, 5 h; (d) 4-methylbenzene-1-sulfonyl chloride, Et₃N, CH₂Cl₂, 0 °C, 12 h; (e) amine, MeCN, 25 °C, 12 h.

Table 2. Enzymatic/Cellular Activity and ADME/Physical Property Data for 10a,b and 11a–f

compd	CK2 α IC ₅₀ (nM) ^a	HCT-116 GI ₅₀ (μ M) ^a	sol. (μ M) ^a	LogD ^a	CL _{int} ^b
10a	<3	0.08	22	1.8	17
10b	<3	0.04	83	1.6	43
11a	<3	0.07	860	2.3	80
11b	<3	0.10	3	2.5	65
11c	<3	0.97	10	1.3	31
11d	<3	0.65	84	1.5	25
11e	<3	0.65	110	1.7	30
11f	<3	0.67	120	1.4	63

^aMean value of at least two experiments. Deviations were within $\pm 25\%$. ^bIntrinsic clearance determined from rat liver microsome incubations (μ L/min/mg).

Table 3. Enzymatic/Cellular Activity and ADME/Physical Property Data for 12a–e

compd	CK2 α IC ₅₀ (nM) ^a	pAKT ^{S129} IC ₅₀ (nM) ^a	HCT-116 GI ₅₀ (μ M) ^a	Sol. (μ M) ^a	LogD ^a	Hu PPB (% free) ^a	CL _{int} ^b	hERG IC ₅₀ (μ M)
12a	<3	ND	0.97	23	2.2	12	<4	ND
12b	<3	28	0.28	13	1.6	28	17	>33
12c	<3	21	0.61	22	1.5	26	6	>33
12d	<3	6	0.059	11	2.2	20	<4	>33
12e	<3	3	0.074	8	2.1	21	<4	>33

12a R₆ = Cl, Y = CH
12b R₆ = Me, Y = CH
12c R₆ = Me, Y = C-F
12d R₆ = CyPr, Y = CH
12e R₆ = CyPr, Y = C-F

^aMean value of at least two experiments. Deviations were within $\pm 25\%$. ^bIntrinsic clearance determined from rat liver microsome incubations (μ L/min/mg); ND = not determined.




Figure 3. Relationship between lipophilicity (logD), human plasma protein binding (log K_i), and microsomal stability (CL_{int}) and the N7 substituent in a series of matched molecular pairs. Markers are colored by the C5 substituent and arranged vertically according to N7 group.

have emerged in the synthetic and medicinal chemistry literature as a versatile functional group with the ability to modulate basicity, confer metabolic stability, and to reduce lipophilicity in drug-like molecules.^{15,16}

A series of N7 3-oxetanyl analogues (**12a–e**) was prepared to compare the effect of this substitution on potency, physical properties, and ADME characteristics. Consistent with our expectations, in a series of matched molecular pairs, this modification lowered logD by ~ 0.8 units, significantly

decreased the fraction of compound bound by human plasma proteins, increased metabolic stability in rat liver microsome and hepatocyte incubations, and reduced activity toward the hERG ion channel (Table 3 and Figure 3). These compounds are potent inhibitors of CK2 (IC₅₀ < 3 nM) but are 10-fold less potent in the mechanistic and phenotypic assays than their N7 cyclopropyl counterparts and, as a consequence, oxetane **12b** possesses comparable activity to the isostructural N7 cyclobutyl derivative **7i** (pAKT IC₅₀ = 0.03 μ M).

However, when the N7 oxetane group is combined with an aniline bearing a cyclopropyl group ortho to the acetamide, as in **12d** and **12e**, cellular potency is improved, presumably due to an overall increase in lipophilicity. The pharmacokinetic profiles of **12d** ($F = 47\%$) and **7b** ($F = 25\%$) in the rat (10 mg/kg, PO) are characterized by good bioavailability and low clearance although the plasma half-life of **12d** ($t_{1/2} = 1.4$ h) is decreased relative to that of **7b** ($t_{1/2} = 2.6$ h) and may be attributed to increased in vivo clearance ($CL = 23$ mL/min/kg). Dissappointingly, the favorable PK characteristics of **12d** were not shared by other analogues in this series; oxetanes **12b** and **12e** exhibit reduced oral bioavailability ($F < 5\%$) and plasma levels ($C_{\max} < 1$ μ M). These results may be explained, at least in part, by considering the aqueous solubility data for **12a–e**, which show little, if any, enhancement relative to the cyclopropyl matched pairs.

Kinase selectivity profiling of **7b** against a panel of 402 kinases revealed a high degree of selectivity (Figure 4).¹⁷




Figure 4. Kinome-wide selectivity profile of **7b**. Red spheres highlight kinases for which the residual activity remaining after treatment with the inhibitor at a concentration of 0.1 μ M/L was less than 45% of DMSO control using a competition binding assay that measures the ability of a compound to compete with an immobilized, active-site directed ligand (KINOMEScan, Discoverx, Inc., San Diego, CA).¹⁸

Limited off-target activity (10 kinases with $>40\%$ inhibition following treatment with **7b** at a concentration of 0.1 μ M/L) was observed against members of the CMGC family, including isoforms of the dual-specificity tyrosine-regulated kinases (Dyrk) and CAMK kinases such as the death-associated protein kinase (Dapk) and histone interacting protein kinase (Hipk) families. Biochemical IC_{50} determinations revealed an activity pattern similar to that of indole **1a** from our earlier work with **7b** exhibiting submicromolar activity against Hipk2 ($IC_{50} = 40$ nM), Dyrk3 ($IC_{50} = 70$ nM), and PIM3 ($IC_{50} = 150$ nM) with weaker effects on GSK3 β ($IC_{50} = 2.6$ μ M) and CDK2 ($IC_{50} = 7.2$ μ M).

On the basis of their physical properties, pharmacokinetic profiles in rodents and dog, and potency against a range of cancer cell lines, **7b** and **7e** were chosen as probes to assess the potential of the series in pharmacodynamic (PD) and disease

model studies. Treatment of murine DLD-1 AKT1 overexpressing xenografts with a single dose of **7b** (10 mg/kg, PO) results in inhibition of pAKT^{S129} at the 3 and 8 h time points, but the effect is not sustained at 24 h. Treatment with **7e** (12.5 mg/kg, PO) also depletes pAKT^{S129} at the early time points and appears to have a partial effect at 24 h as determined by Western blot analysis (Figure 5). Dose/response plots




Figure 5. (a) Western blot analysis of pAKT^{S129} levels in tumor cell lysates following administration of **7b** (10 mg/kg, PO) and **7e** (12.5 mg/kg, PO) in a DLD-1 AKT1 overexpressing murine xenograft model. (b) Dose/response plot illustrating pAKT^{S129} levels (red) in tumor cell lysates, as determined by ELISA, versus plasma concentration of **7b** (blue).

illustrating pAKT^{S129} inhibition following treatment with **7b**, as measured by ELISA of tumor cell lysates, indicate residual inhibition of pAKT^{S129} at later time points, when no detectable drug remains in plasma. Compound **7b** showed limited tumor growth inhibition when tested using a once daily 10 mg/kg oral dose (TGI = 28%) or a twice daily 5 mg/kg oral dose (TGI = 37%) for 14 days in disease model studies using a murine DLD-1 xenograft.

In particular, we have demonstrated that 3-amino oxetane derivatives exhibit reduced lipophilicity, decreased affinity for plasma proteins, and reduced hERG ion channel binding. Additional studies to determine the relationship between exposure and pharmacodynamic response for these and related agents in vivo will be described in subsequent communications.¹⁹

■ ASSOCIATED CONTENT

Supporting Information

Representative experimental procedures for synthesis of analogues, biochemical and cellular assays, and X-ray structure determination. This material is available free of charge via the Internet at <http://pubs.acs.org>.

■ AUTHOR INFORMATION

Corresponding Author

*(J.E.D.) Tel: 781-839-3900. E-mail: james.dowling@astrazeneca.com.

Notes

The authors declare no competing financial interest.

■ REFERENCES

- (1) Ruzzene, M.; Pinna, L. A. Addiction to protein kinase CK2: A common denominator of diverse cancer cells? *Biochim. Biophys. Acta* **2010**, *1804*, 499–504.
- (2) Di Maira, G.; Brustolon, F.; Pinna, L. A.; Ruzzene, M. Dephosphorylation and inactivation of Akt/PKB is counteracted by protein kinase CK2 in HEK 293T cells. *Cell. Mol. Life Sci.* **2009**, *66*, 3363–3373.
- (3) Dominguez, I.; Sonenshein, G. E.; Seldin, D. C. CK2 and its role in Wnt and NF-kappa B signaling: Linking development and cancer. *Cell. Mol. Life Sci.* **2009**, *66*, 1850–1857.
- (4) Laramas, M.; Pasquier, D.; Filhol, O.; Ringeisen, F.; Descotes, J.-L.; Cochet, C. *Eur. J. Cancer* **2007**, *43*, 928–934.
- (5) Ji, H.; Wang, J.; Nika, Trembley, J. H.; Unger, G. M.; Tobolt, D. K.; Korman, V. L.; Wang, G.; Ahmad, K. A.; Slaton, J. W.; Kren, B. T.; Ahmed, K. Systemic administration of antisense oligonucleotides simultaneously targeting CK2alpha and alpha' subunits reduces orthotopic xenograft prostate tumors in mice. *Mol. Cell. Biochem.* **2011**, *356*, 21–35.
- (6) Sarno, S.; Papinutto, E.; Franchin, C.; Bain, J.; Elliott, M.; Meggio, F.; Kazimierczuk, Z.; Orzeszko, A.; Zanotti, G.; Battistutta, R.; Pinna, L. A. ATP site-directed inhibitors of protein kinase CK2: an update. *Curr. Top. Med. Chem.* **2011**, *11*, 1340–1351.
- (7) Pierre, F.; Chua, P. C.; O'Brien, S. E.; Siddiqui-Jain, A.; Bourbon, P.; Haddach, M.; Michaux, J.; Nagasawa, J.; Schwaebe, M. K.; Stefan, E.; Vialettes, A.; Whitten, J. P.; Chen, T. K.; Darjania, L.; Stansfield, R.; Anderes, K.; Bliesath, J.; Drygin, D.; Ho, C.; Omori, M.; Proffitt, C.; Streiner, N.; Trent, K.; Rice, W. G.; Ryckman, D. M. Discovery and SAR of 5-(3-chlorophenylamino)benzo[c][2,6] naphthyridine-8-carboxylic acid (CX-4945), the first clinical stage inhibitor of protein kinase CK2 for the treatment of cancer. *J. Med. Chem.* **2011**, *54*, 635–644.
- (8) Dowling, J. E.; Bao, L.; Brassil, P.; Chen, H.; Chuaqui, C.; Cooke, E. L.; Denz, C. R.; Larsen, N. A.; Lyne, P. D.; Peng, B.; Pontz, T. W.; Racicot, V.; Russell, D.; Su, N.; Thakur, K.; Wu, A.; Ye, Q.; Zhang, T. Potent and selective inhibitors of CK2 kinase identified through structure-guided hybridization. *ACS Med. Chem. Lett.* **2012**, *3*, 278–283.
- (9) Di Maira, G.; Brustolon, F.; Pinna, L. A.; Ruzzene, M. Dephosphorylation and inactivation of Akt/PKB is counteracted by protein kinase CK2 in HEK 293T cells. *Cell. Mol. Life Sci.* **2009**, *66*, 3363–3373.
- (10) Kranenburg, M.; van der Burgt, Y. E. M.; Kamer, P. C. J.; van Leeuwen, P. W. N. M.; Goubitz, K.; Fraanje, J. New diphosphine ligands based on heterocyclic aromatics inducing very high regioselectivity in rhodium-catalyzed hydroformylation: effect of the bite angle. *Organometallics* **1995**, *14*, 3081–3089.
- (11) See Supporting Information.
- (12) PDB deposition code for the cocrystal structure is 4GUB.
- (13) Nie, Z.; Perretta, C.; Erickson, P.; Margosiak, S.; Almasy, R.; Lu, J.; Averill, A.; Yager, K. M.; Chu, S. Structure-based design, synthesis, and study of pyrazolo[1,5-a][1,3,5]triazine derivatives as potent inhibitors of protein kinase CK2. *Bioorg. Med. Chem. Lett.* **2007**, *17*, 4191–4195.
- (14) Figure produced using Pymol. DeLano, W. L. *The PyMOL Molecular Graphics System*; DeLano Scientific: San Carlos, CA, 2002; see <http://www.pymol.org>.
- (15) Wuitschik, G.; Carreira, E. M.; Wagner, B.; Fischer, H.; Parrilla, I.; Schuler, F.; Rogers-Evans, M.; Müller, K. Oxetanes in drug discovery: Structural and synthetic insights. *J. Med. Chem.* **2010**, *53* (8), 3227–3246.
- (16) Burkhard, J. A.; Wuitschik, G.; Rogers-Evans, M.; Müller, K.; Carreira, E. M. Oxetanes as versatile elements in drug discovery and synthesis. *Angew. Chem., Int. Ed.* **2010**, *49* (48), 9052–9067.
- (17) Karaman, M. W.; Herrgard, S.; Treiber, D. K.; Gallant, P.; Atteridge, C. E.; Campbell, B. T.; Chan, K. W.; Ciceri, P.; Davis, M. L.; Edeen, P. T.; Faraoni, R.; Floyd, M.; Hunt, J. P.; Lockhart, D. J.; Milanov, Z. V.; Morrison, M. J.; Pallares, G.; Patel, H. K.; Pritchard, S.; Wodicka, L. M.; Zarrinkar, P. P. A quantitative analysis of kinase inhibitor selectivity. *Nat. Biotechnol.* **2008**, *26*, 127–132.
- (18) Image generated using TREEspot Software Tool and reprinted with permission from KINOMEScan, a division of DiscoveRx Corporation, © DISCOVERX CORPORATION 2010.
- (19) Dowling, J. E.; Alimzhanov, M.; Bao, L.; Chuaqui, C.; Denz, C.; Ferguson, A.; Graff, C.; Liu, Z.-Y.; Lyne, P.; Racicot, V.; Wu, A.; Wu, J.; Ye, Q.; Cooke, E. L. Discovery and characterization of AZ968, a potent and selective inhibitor of CK2 kinase with effects on AKT signaling in vivo. Poster presented at the 103rd Annual Meeting of the American Association for Cancer Research, March 31–April 4, 2012. Chicago, IL; Abstract No. 3907.